Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus.
Saga R, Fujimoto A, Watanabe N, Matsuda M, Hasegawa M, Watashi K, Aizaki H, Nakamura N, Tajima S, Takasaki T, Konishi E, Kato T, Kohara M, Takeyama H, Wakita T, Suzuki R.
Saga R, et al. Among authors: takeyama h.
Sci Rep. 2016 Jun 27;6:28688. doi: 10.1038/srep28688.
Sci Rep. 2016.
PMID: 27345289
Free PMC article.